Personalized management in functional gastrointestinal disorders based on genomics: hope at last or just feigned praise?

With the arrival of technology that has facilitated deoxyribonucleic acid (DNA) testing, there is an increasing push from both physicians and patients to practice precision medicine with the goal of maximizing therapeutic benefits and minimizing adverse events. The recently published Rome Foundation Working Team Report cites pharmacogenomic testing as a potential tool for optimizing neuromodulator use as primary or augmentation therapy.1 The interest in precision medicine has also been increasing in medical2–4 as well as lay media questioning its true utility.5 In light of this interest, we seek to provide a review of the role of pharmacogenomics in the treatment of functional gastrointestinal (GI) diseases